KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Liabilities (2018 - 2025)

Vir Biotechnology's Total Liabilities history spans 8 years, with the latest figure at $237.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 4.38% year-over-year to $237.5 million; the TTM value through Dec 2025 reached $237.5 million, down 4.38%, while the annual FY2025 figure was $237.5 million, 4.38% down from the prior year.
  • Total Liabilities for Q4 2025 was $237.5 million at Vir Biotechnology, up from $223.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $886.1 million in Q1 2022 and bottomed at $223.4 million in Q3 2025.
  • The 5-year median for Total Liabilities is $331.4 million (2021), against an average of $413.5 million.
  • The largest annual shift saw Total Liabilities skyrocketed 400.75% in 2021 before it plummeted 64.52% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $522.4 million in 2021, then skyrocketed by 38.61% to $724.1 million in 2022, then crashed by 54.59% to $328.8 million in 2023, then decreased by 24.45% to $248.4 million in 2024, then dropped by 4.38% to $237.5 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Total Liabilities are $237.5 million (Q4 2025), $223.4 million (Q3 2025), and $245.1 million (Q2 2025).